

Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma

Information for the public

Published: 17 October 2018

www.nice.org.uk

Dabrafenib (Tafinlar) with trametinib (Mekinist) is available on the NHS. It is a possible treatment for melanoma that has the BRAF V600 mutation in adults, if:

- the tumour has been removed by surgery (known as resected) and
- it has spread into nearby lymph nodes (known as stage 3).

Adjuvant treatment can help keep the cancer from coming back.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Melanoma UK](#), 0808 171 2455
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3150-7